A common class of medications used to treat type 2 diabetes-sulfonylureas like glimepiride, glipizide, and glyburide-may inadvertently worsen the condition over time, according to a new study published in Diabetes, Obesity and Metabolism. While frequently prescribed despite the availability of choice drugs, research suggests these medications can impair the function of insulin-producing cells. The findings offer insight into why some patients experience diminishing returns from sulfonylureas and coudl pave the way for more effective treatment strategies.
A widely used diabetes medication, a mainstay in treating type 2 diabetes for decades, may worsen the condition over time by diminishing the ability of insulin-producing cells to function properly, a new scientific study warns.
The medications in question belong to a class called “sulfonylureas,” and include glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (DiaBeta, Micronase). Despite the availability of newer and potentially safer drugs, these older medications remain commonly prescribed for diabetes management.
Researchers from the University of Barcelona, the Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, and the CIBERDEM center for research into diabetes and associated metabolic diseases, found that sulfonylureas may interfere with the function of pancreatic beta cells – the cells responsible for producing insulin. This interference can lead to a loss of the cells’ specialized identity, leaving them alive but unable to effectively secrete insulin, according to the study published in Diabetes, Obesity and Metabolism.
Laboratory results showed that cells treated with these drugs gradually lost their core ability to produce insulin, accompanied by decreased activity of genes associated with their function and an increased rate of cell death. This finding is significant because it sheds light on why some patients experience a decline in the drug’s effectiveness over time.
The researchers link this phenomenon to increased stress within the cell’s endoplasmic reticulum, which is responsible for manufacturing vital proteins like insulin. Understanding these cellular mechanisms is crucial for developing more effective diabetes treatments.
This effect is believed to be the cause of what doctors refer to as “sulfonylurea failure,” where the medication becomes less effective with prolonged use. However, the researchers emphasize that the issue isn’t complete cell death, but rather a “loss of functional identity,” which theoretically could be reversible. This opens the possibility of developing new therapies that can restore beta cells’ ability to produce insulin naturally.
The research team stresses that these findings do not mean patients should immediately stop taking their medication. Instead, they highlight the importance of regular follow-up with a physician, particularly given the availability of newer and safer treatment options. Maintaining consistent care and exploring alternative therapies can help patients effectively manage their diabetes and minimize potential long-term complications.
اقترح تصحيحاً
